Not for the first time, the agency takes steps that could determine whether carbadox, a cancer-causing livestock drug, should remain on the market.... Research shows that carbadox could actually be speeding up the antibiotic resistance of Salmonella and E. coli.
Scott Olson/Getty Images
Not for the first time, the agency takes steps that could determine
whether carbadox, a cancer-causing livestock drug, should remain on
the market.
You may not have heard of an antibiotic called carbadox, but its
usage in treating sick swine has been common in the U.S. since the
‘70s—despite the fact that it’s a likely carcinogen, shown to cause
tumors in lab animals. In fact, the Food and Drug Administration
(FDA) was seeking to ban carbadox back in 2016 at the tail end of
the Obama administration, going so far as to announce that it
intended to allow the drug maker to request a hearing on the matter.
That never happened.
“Things pretty much just stalled during the next four years, as we
had the new administration coming in,” said Steven Roach, Safe and
Healthy Food Program director for humane farming nonprofit Food
Animal Concerns Trust (FACT). According to a spokesman for FDA, who
answered questions from The Counter via email, the agency backed
away from its original plan after it determined that the main
concern about carbadox centered on the inadequacy of the method drug
maker Phibro Animal Health used to measure carcinogenic residues in
pork tissue.
So, on March 10, the agency held a public hearing on that
measurement method. If FDA decides that method should be revoked,
the agency will pursue yet another hearing—the next one to
potentially ban carbadox use in hogs. The FDA spokesman said this
could lead to the agency withdrawing approval of all new animal drug
applications for carbadox’s use. This effective ban would put the
U.S. in line with the European Union, Canada, and Australia, where
carbadox has been disallowed for a number of years.
Carbadox is added to livestock feed to control diarrhea in young
pigs after they are weaned from their mothers, as well as to promote
their growth (despite a federal ban on antibiotic use for growth
promotion, it’s allowed for carbadox). And though Phibro leaned
heavily on the drug’s medical necessity at last week’s hearing,
company marketing materials focus primarily on how carbadox helps
fatten pigs rapidly. FACT, the only group to present anti-carbadox
comments at FDA’s hearing, estimates that over 50 percent of U.S.
hog farmers use the drug, while Bloomberg put that estimate
considerably higher—90 percent. Although FDA explicitly disallows
carcinogenic drugs in treating animals, a proviso allows their use
if no residues of them are “found by an approved regulatory method
in any edible tissues of or foods from the animal.” Phibro maintains
that its continued use in hogs is essential to production, and to
human health.
Though Phibro leaned heavily on the drug’s medical necessity at last
week’s hearing, company marketing materials focus primarily on how
carbadox helps fatten pigs rapidly.
“The drugs to which veterinarians would turn to replace carbadox
are, in many cases, medically important antibiotics in human
medicine, things like aminoglycosides, which…FDA has deemed…to be
medically important in humans,” said lawyer Jeannie Perron, speaking
on behalf of Phibro in last week’s hearing. “But if carbadox were
not available, swine veterinarians would be forced to use drugs like
that.” She insisted on multiple occasions that carbadox use was
safe, despite the fact that residue measurements used in Canada, for
example, find carcinogenic residues where Phibro’s methods do not.
(Phibro did not respond to requests for comment from The Counter.)
Other proponents of the drug who spoke during the hearing claimed
that banning the drug would result in increased animal suffering and
death. “It’s my job to advocate for the pig,” said Clayton Johnson,
a livestock veterinarian. Without carbadox, “Our pig populations
will get sick [and] animal caretakers will be frustrated,” he said.
Rather than presenting FDA with a new method for detecting carbadox
residues, which it had been invited to do, Phibro representatives
doubled down in insisting that their old methods were adequate, and
suggested FDA could come up with an alternate testing method on its
own.
Narrow though the scope of this particular hearing was, FACT’s Roach
pointed out that the issues of concern with carbadox go beyond
carcinogenic residues in pork tissue. For starters, “Workers who are
handling the drug and putting it into feed can be exposed through
inhaling [carbadox] dust, and we’ve seen some reports of absorption
of carbadox through the skin,” he said, mentioning that worker
safety was a concern cited by the EU in banning the drug.
“These facilities have continuous problems of swine dysentery and we
keep putting new pigs in them and adding a bunch of drugs to their
feed.”
Additionally, United States Geological Survey (USGS) has found
evidence of carbadox in some surface waters in the U.S. This sort of
environmental exposure through water “is another scary outlet that
we’re seeing,” said Roach’s FACT colleague, Safe and Healthy Food
Program associate Madeleine Kleven, who spoke at the FDA hearing.
“We don’t know the risk this poses, but it could be even more
dangerous”—not just to humans but to wildlife as well. As with
determining the full extent of human cancer risk from carbadox meat
residues, understanding the effects of carbadox in water would
necessitate scientific study; Roach and Kleven were unaware of any
such studies.
Perhaps most troubling, however, is research showing that carbadox
could actually be speeding up the antibiotic resistance of
Salmonella and E. coli. “Relevant to the question of whether
carbadox should be considered medically important, some of the
transferred genes coded for resistance to antibiotic classes that
are commonly used in human medicine, including tetracyclines,
aminoglycosides, and beta-lactams,” according to the authors of one
study.
Carbadox proponents say that hog farmers in the EU are suffering
losses as a result of the continent’s carbadox ban, a challenge that
Roach said is accurate, and of concern. “They are having some
trouble with resistant swine dysentery, a disease that causes bloody
diarrhea, and that’s a real issue,” he said. Still, he said a bigger
concern—both there and here—is the unhealthy systems in which hogs
are raised. “These facilities have continuous problems of swine
dysentery and we keep putting new pigs in them and adding a bunch of
drugs to their feed.” If hog farmers and veterinarians were
concerned with animal welfare, they’d “clean out the facility and
make sure [it’s] clean.” Additionally, since young hogs get diarrhea
when they’re weaned from their mothers at the age of 20 days—too
early for their guts to handle solid food—another logical solution
would be to “give them another 10 days, so you wouldn’t need to use
antibiotics,” Roach said.
Next up for the FDA is to post a transcript of the hearing on its
website “as soon as possible,” to review any comments and other
submitted information regarding carbadox, then to determine further
steps. The FDA spokesperson did not offer a more detailed timeline
for these proceedings.
Lela Nargi is a veteran journalist covering food policy and agriculture, sustainability, and science for outlets such as the Washington Post, JSTOR Daily, Sierra, Ensia, and Civil Eats. Find her at lelanargi.com.